Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keiko Udaka

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Cancer Medicine|May 15, 2025
Transcutaneous Imiquimod Combined With Anti-Programmed Cell Death-1 Monoclonal Antibody Extends the Survival of Mice Bearing Renal Cell CarcinomaTakashi Karashima, Toshihiro Komatsu, Shinkuro Yamamoto, et al.
Nature Communications|September 21, 2022
The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognitionChihiro Motozono, Mako Toyoda, Toong Seng Tan, et al.
Cancer Immunology, Immunotherapy : CII|July 17, 2021
Identification of mouse helper epitopes for WT1-specific CD4<sup>+</sup> T cellsHiroko Nakajima, Jun Nakata, Kanako Imafuku, et al.
Microbiology and Immunology|June 21, 2007
WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinomaTatsuo Iiyama, Keiko Udaka, Sachihiko Takeda, et al.
International Journal of Hematology|August 5, 2003
Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosisYoshihiro Oka, Akihiro Tsuboi, Masaki Murakami, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 7, 2007
Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytesFumihiro Fujiki, Yoshihiro Oka, Akihiro Tsuboi, et al.
Microbiology and Immunology|December 19, 2008
Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitopeZheyu Li, Yoshihiro Oka, Akihiro Tsuboi, et al.
Frontiers in Immunology|May 13, 2026
N-terminal pyroglutamylation of an HLA-A24-restricted immunodominant epitope enhances SARS-CoV-2-specific T-cell responsesYoshiki Aritsu, Masahiro Kitabatake, Amiri Kurose, et al.
Cancer Immunology, Immunotherapy : CII|November 20, 2002
Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residuesAkihiro Tsuboi, Yoshihiro Oka, Keiko Udaka, et al.
International Journal of Hematology|January 15, 2008
Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myelomaAkihiro Tsuboi, Yoshihiro Oka, Hiroko Nakajima, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Cancer Medicine|May 15, 2025
Transcutaneous Imiquimod Combined With Anti-Programmed Cell Death-1 Monoclonal Antibody Extends the Survival of Mice Bearing Renal Cell CarcinomaTakashi Karashima, Toshihiro Komatsu, Shinkuro Yamamoto, et al.
Nature Communications|September 21, 2022
The SARS-CoV-2 Omicron BA.1 spike G446S mutation potentiates antiviral T-cell recognitionChihiro Motozono, Mako Toyoda, Toong Seng Tan, et al.
Cancer Immunology, Immunotherapy : CII|July 17, 2021
Identification of mouse helper epitopes for WT1-specific CD4<sup>+</sup> T cellsHiroko Nakajima, Jun Nakata, Kanako Imafuku, et al.
Microbiology and Immunology|June 21, 2007
WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinomaTatsuo Iiyama, Keiko Udaka, Sachihiko Takeda, et al.
International Journal of Hematology|August 5, 2003
Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosisYoshihiro Oka, Akihiro Tsuboi, Masaki Murakami, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 7, 2007
Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytesFumihiro Fujiki, Yoshihiro Oka, Akihiro Tsuboi, et al.
Microbiology and Immunology|December 19, 2008
Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitopeZheyu Li, Yoshihiro Oka, Akihiro Tsuboi, et al.
Frontiers in Immunology|May 13, 2026
N-terminal pyroglutamylation of an HLA-A24-restricted immunodominant epitope enhances SARS-CoV-2-specific T-cell responsesYoshiki Aritsu, Masahiro Kitabatake, Amiri Kurose, et al.
Cancer Immunology, Immunotherapy : CII|November 20, 2002
Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residuesAkihiro Tsuboi, Yoshihiro Oka, Keiko Udaka, et al.
International Journal of Hematology|January 15, 2008
Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myelomaAkihiro Tsuboi, Yoshihiro Oka, Hiroko Nakajima, et al.
Pageof 5